Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
Not Applicable
Recruiting
- Conditions
- Endometrial Cancer
- Interventions
- Other: tumour and blood samples
- Registration Number
- NCT06603506
- Lead Sponsor
- Centre Francois Baclesse
- Brief Summary
This study comprises 3 stages:
1. Collection of tumor and blood samples.
2. Creation of organoid models based on tumor samples.
3. Development of functional tests to predict clinical response to treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 16
Inclusion Criteria
-
Patient aged 18 years or more
-
Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
-
Patient with localized endometrial cancer, presenting:
- A high-grade endometrioid histological type and/or
- P53 mutation and/or
- a non-endometrioid histological type regardless of P53 status.
-
Patient affiliated to a social security scheme
-
Information and signature of informed consent prior to any specific study procedure
Exclusion Criteria
- Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
- Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description tumour and blood collection tumour and blood samples tumour and blood collection for realization ex vivo organoid models
- Primary Outcome Measures
Name Time Method Rate of establishment of exploitable tumor organoid lines through study completion, an average of 3 years Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre François Baclesse
🇫🇷Caen, France